Mustang Bio gets second 180-day window to fix Nasdaq bid price deficiency

Mustang Bio, Inc. disclosed in an 8-K filing dated October 13, 2026 that Nasdaq had extended its deadline for regaining compliance with the exchange's minimum bid price rule. The company had been notified on April 15, 2026 that its stock closed below $1.00 for 30 consecutive business days, putting it out of compliance with Nasdaq Listing Rule 5550(a)(2).¹

Mustang Bio had an initial 180-day grace period running to October 12, 2026 to fix the deficiency, but it could not show compliance by that date.¹ The company then asked Nasdaq for a second 180-day grace period, arguing that as of October 12 it met the market value requirement for publicly held shares and all other initial listing standards apart from the bid price rule, and it told Nasdaq it intended to pursue a reverse stock split if needed to fix the problem.¹

On October 13, 2026, Nasdaq's Staff agreed to the request, giving the company until April 12, 2027 to regain compliance.¹ To satisfy the rule, Mustang Bio's stock needs to close at $1.00 or above for at least 10 straight business days, though Nasdaq can require up to 20 consecutive days of compliance.¹

If the company still falls short by the end of the new grace period, Nasdaq will issue a delisting notice, though Mustang Bio could appeal to the Nasdaq Hearings Panel, a step that would not stop a trading suspension from taking effect.¹ The company said it plans to track its stock price and pursue options including a reverse split to stay listed, while cautioning there is no guarantee it will meet all continued listing requirements.¹

The filing was signed by Manuel Litchman, M.D., President, Chief Executive Officer and Interim Chief Financial Officer¹, on October 15, 2026.